tradmap

ARTV Earnings Artiva Biotherapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$36 -$18 $0 2023 2024 2025
EPS
Revenue (annual)
$0 $17M $33M 2023 2024 2025
Revenue
Net income (annual)
-$84M -$42M $0 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$39 -$20 $0 Q2 '23 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Revenue (quarterly)
$0 $13M $27M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$25M -$7M $11M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–13 of 13
Q2 20262026-06-30-1.512026-08-0610-Q
Q1 20262026-03-31-0.952026-05-0810-Q
FY 20252025-12-31-3.432026-03-1010-K
Q3 20252025-09-30-2.592025-11-1210-Q
Q2 20262025-06-30-1.712026-08-0610-Q
Q1 20262025-03-31-0.832026-05-0810-Q
FY 20252024-12-31-5.812026-03-1010-K
Q3 20252024-09-30-7.162025-11-1210-Q
Q2 20252024-06-30-39.242025-08-0610-Q
Q1 20252024-03-31-17.242025-05-0810-Q
FY 20242023-12-31-35.782025-03-2410-K
Q3 20242023-09-30-20.892024-11-1210-Q
Q2 20242023-06-30-35.122024-08-2910-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.